

CHAMPIONS BIOTECHNOLOGY, INC.  
Form 8-K  
July 28, 2010

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 28, 2010

CHAMPIONS BIOTECHNOLOGY, INC.  
(Exact name of registrant as specified in its charter)

<b>Delaware</b> (State or other Jurisdiction of Incorporation)	<b>0-17263</b> (Commission File Number)	<b>52-1401755</b> (IRS Employer Identification No.)
--	--	--

**Science and Technology Park at Johns Hopkins**  
**855 N. Wolfe Street, Suite 619, Baltimore, MD**      **21205**  
(Address of Principal Executive Offices)      (Zip Code)  
Registrant's telephone number, including area code: **(410) 369-0365**

**Inapplicable**

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**INFORMATION TO BE INCLUDED IN THE REPORT**

**Item 2.02. Results of Operations and Financial Condition.**

On July 28, 2010, Champions Biotechnology, Inc. (the **Company** ) announced its results of operations for its fiscal year ended April 30, 2010. A copy of the Company's press release announcing such results dated July 28, 2010 is attached hereto as Exhibit 99.1. This Form 8-K and the attached exhibit are furnished to, but not filed with, the Securities and Exchange Commission ( **SEC** ) and shall not be deemed to be incorporated by reference into any of the Company's filings with the SEC under the Securities Act of 1933.

**Item 9.01. Financial Statements and Exhibits.**

*(c) Exhibits*

The following exhibits are filed herewith:

Exhibit No.

99.1 Press Release dated July 28, 2010

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**CHAMPIONS BIOTECHNOLOGY, INC.**  
(Registrant)

Date: July 28, 2010

By: /s/ Mark Schonau  
Mark Schonau  
Chief Financial Officer